This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Chiharu Matsumura: Innovator in Cyanotriazole Compounds
Introduction
Chiharu Matsumura is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of medicinal chemistry, particularly through her innovative work on cyanotriazole compounds. Her research focuses on developing compounds that can effectively stimulate the citric acid cycle and improve hyperglycemia, offering potential therapeutic benefits for various metabolic disorders.
Latest Patents
Chiharu Matsumura holds a patent for a cyanotriazole compound, which is represented by a specific chemical formula. This compound or its salts are designed to enhance citric acid cycle activity and improve hyperglycemia with minimal side effects. The invention is particularly useful in treating and preventing diseases such as diabetes, insulin resistance, and cardiovascular conditions, among others.
Career Highlights
Matsumura is currently associated with Otsuka Pharmaceutical Company, Limited, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of metabolic diseases and exploring new therapeutic avenues.
Collaborations
Throughout her career, Chiharu Matsumura has collaborated with notable colleagues, including Seiji Sato and Satoshi Matsuda. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Chiharu Matsumura's contributions to the field of medicinal chemistry, particularly through her cyanotriazole compounds, highlight her role as a leading inventor. Her work not only addresses critical health issues but also paves the way for future advancements in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
